BRIEF—BASF launches Hepaxa in USA for chronic liver disease

Germany-based BASF, the world’s largest chemical company, is introducing Hepaxa, a product that can help tens of millions of patients manage non- alcoholic fatty liver disease (NAFLD), one of the most common forms of chronic liver disease.

Providing highly concentrated and pure eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), Hepaxa is the first product in the USA specifically designed to address a build-up of fat in the liver, known as steatosis, in NAFLD patients.

Hepaxa will be distributed nationally through DIEM Labs.

Studies have shown that NAFLD patients are deficient in EPA and DHA. Hepaxa increases the levels of these important fatty acids in the blood, which improves the liver´s ability to process excessive fat stored there while inhibiting the conversion of dietary carbohydrates into fat.

A 2017 BASF study has shown that Hepaxa is effective and safe in the dietary management of NAFLD patients.

BASF plans to publish the clinical results of this product-specific human intervention trial in the second half of 2018.